Malignant peripheral nerve sheath tumor epidemiology and demographics: Difference between revisions
No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Malignant peripheral nerve sheath tumor}} | {{Malignant peripheral nerve sheath tumor}} | ||
{{CMG}}; {{AE}} {{SC}} | |||
==Overview== | |||
They are estimated to account for 5-10% of all soft-tissue sarcomas. They typically present in adults. There is no recognised gender predilection and clinical presentation varies dependant on location. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Line 8: | Line 11: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Neurology]] | [[Category:Neurology]] |
Revision as of 16:08, 2 December 2015
Malignant peripheral nerve sheath tumor Microchapters |
Differentiating Malignant Peripheral Nerve Sheath Tumor from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Malignant peripheral nerve sheath tumor epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Malignant peripheral nerve sheath tumor epidemiology and demographics |
FDA on Malignant peripheral nerve sheath tumor epidemiology and demographics |
CDC on Malignant peripheral nerve sheath tumor epidemiology and demographics |
Malignant peripheral nerve sheath tumor epidemiology and demographics in the news |
Blogs on Malignant peripheral nerve sheath tumor epidemiology and demographics |
Directions to Hospitals Treating Malignant peripheral nerve sheath tumor |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Overview
They are estimated to account for 5-10% of all soft-tissue sarcomas. They typically present in adults. There is no recognised gender predilection and clinical presentation varies dependant on location.